Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.

Jutta GärtnerStephen L HauserAmit Bar-OrXavier MontalbanJeffrey A Cohen Anne H CrossKumaran DeivaHabib GanjgahiDieter A HäringBingbing LiRatnakar PingiliKrishnan RamanathanWendy SuRoman WilliBernd KieseierLudwig Kappos

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)

The favourable benefit-risk profile of ofatumumab versus teriflunomide supports its consideration as a first-line therapy in RDTN patients.ASCLEPIOS I and II are registered at ClinicalTrials.gov (NCT02792218 and NCT02792231).

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
hiv infected
combination therapy
replacement therapy
cell therapy